– USA, MA – PathMaker Neurosystems Inc., a clinical-stage neuromodulation company pioneering a breakthrough non-invasive treatment approach for amyotrophic lateral sclerosis, announced the appointment of Dr. Pritesh Shah (Pharm.D.) to its Board of Directors.
About Dr. Pritesh Shah
Dr. Shah previously served as CGO and CCO at Novocure, a publicly-traded medtech company that pioneered the treatment of cancer using electrical fields, where he was instrumental in leading global commercial and patient operations, significantly increasing revenue in key markets.
Throughout his career, Pritesh Shah has held influential roles in commercial and medical affairs at leading companies, including Roche/Genentech, Bristol Myers Squibb, and OSI Oncology.
Dr. Shah holds a Doctor of Pharmacy from the University of Maryland and advanced degrees in communications and leadership from Seton Hall University and the Yale School of Management.
About PathMaker Neurosystems Inc.
PathMaker Neurosystems is a clinical-stage neuromodulation company pioneering a breakthrough non-invasive approach to the treatment of amyotrophic lateral sclerosis. From its headquarters in Boston, PathMaker is collaborating with world-class institutions to develop and bring to market first-in-class products for treating ALS and other neurological disorders with very high unmet medical needs. More than 30,000 people in the U.S. suffer from ALS, with an additional 6,000 new ALS diagnoses each year in the U.S. The MyoRegulator platform is based on PathMaker’s proprietary technology for multi-site direct current stimulation (Multi-Site DCS). MyoRegulator has been previously designated by the US Food and Drug Administration (FDA) as a “FDA Breakthrough Device.” MyoRegulator and MyoRegulator ALS are investigational medical devices and are limited by Federal law to investigational use only.
For more: https://pmneuro.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.